Ifosfamide

Generic Name: Ifosfamide

Brand Names: Ifex

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 3778-73-2

Unique Ingredient Identifier: UM20QQM95Y

Background: Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication: Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.

Associated Conditions: Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma

Associated Therapies: -

Clinical Trials

Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: ifosfamide
Drug: O6-benzylguanine

First Posted Date: 2004-07-12

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT00086970

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-07-08

Last Posted Date: 2013-06-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00003198

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Sarcoma

Interventions: Biological: filgrastim
Drug: doxorubicin hydrochloride
Drug: ifosfamide
Drug: mesna
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: brachytherapy
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-07-01

Last Posted Date: 2014-07-25

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 43

Registration Number: NCT00002804

Locations: 🇺🇸
Via Christi Regional Medical Center, Wichita, Kansas, United States
🇺🇸
MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States
🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

and more 6 locations

Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: bleomycin sulfate
Drug: CHOP regimen
Drug: cisplatin
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: cytarabine
Drug: prednisone
Drug: etoposide
Drug: idarubicin
Drug: ifosfamide
Drug: mesna
Drug: methylprednisolone
Drug: mitoxantrone hydrochloride
Drug: vincristine sulfate

First Posted Date: 2004-06-30

Last Posted Date: 2018-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 61

Registration Number: NCT00002565

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇧🇷
Faculdade de Medicina do ABC, Sao Paulo, Brazil
🇨🇱
Clinica Alemana, Santiago, Chile

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: cytarabine
Drug: dexamethasone
Drug: etoposide
Drug: idarubicin
Drug: ifosfamide
Drug: leucovorin calcium
Drug: mesna
Drug: pegaspargase
Drug: therapeutic hydrocortisone
Drug: thioguanine
Drug: vincristine sulfate
Radiation: low-LET electron therapy
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET photon therapy
Drug: Methotrexate

First Posted Date: 2004-06-23

Last Posted Date: 2013-08-22

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 120

Registration Number: NCT00002816

Locations: 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Kaplan Cancer Center, New York, New York, United States

and more 30 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-06-16

Last Posted Date: 2021-02-21

Lead Sponsor: UNICANCER

Target Recruit Count: 36

Registration Number: NCT00003860

Locations: 🇫🇷
Hopitaux Universitaire de Strasbourg, Strasbourg, France
🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷
CHRU de Nancy - Hopitaux de Brabois, Vandoeuvre-Les-Nancy, France

and more 19 locations

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Oral Complications

First Posted Date: 2004-05-25

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 111

Registration Number: NCT00004061

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: recombinant interleukin-12
Drug: etoposide
Drug: ifosfamide

First Posted Date: 2004-05-20

Last Posted Date: 2013-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00003575

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University Hospital/New Jersey Cancer Center, Newark, New Jersey, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 7 locations